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Excitatory amino acids, glutamate in particular, have
a marked stimulatory effect on the reproductive axis,
particulary at puberty. Glutamate, N-methyl-D-aspartate
(NMDA), and kainite-stimulate gonadotropin-releas-
ing hormone (GnRH) secretion in immature mammals
and NMDA receptor stimulation results in precocious
puberty in rats and monkeys. Puberty is characterized
by an increased sensitivity of GnRH to glutamate as
well as an increase in glutaminase activity in the hypo-
thalamus. Glutamatergic and GABAergic regulation of
GnRH secretion seem strongly interdependent around
puberty. In addition to the transsynaptic glutamatergic
regulation of GnRH secretion, a coordinated activity
of glutamatergic neurons and astroglial cells has been
shown to play an active role in puberty. The partic-
ipation of kainate receptors in the estradiol-induced
advancement of puberty suggest that these receptors
may be involved in the estradiol-mediated activa-
tion of GnRH secretion at puberty. A case of precocious
puberty associated with hyperglycinemia illustrates
the NMDA involvement in puberty in humans. In this
patient, the occurrence of precocious puberty was
thought to result from excessive stimulation by glycine
of the NMDA receptors linked to the GnRH neurons.
Glutamate plays several roles in the hypothalamic
mechanism of puberty as it has been shown in animal
models, but there are still few clinical data supporting
the role of glutamate in human puberty.
Key Words: Glutamate; NMDA; kainate; GnRH; estra-
diol; glia; hypothalamus.
Introduction
Excitatory amino acids (EAA), glutamate in particular,
play a preeminent role in the control of brain functions. Glu-
tamate and its receptors are expressed in the hypothala-
mus and are involved in key reproductive and neuroendo-
crine processes such as puberty, preovulatory surge, repro-
ductive behavior, and stress. Glutamate receptors are either
metabotropic, G protein–coupled receptors or ionotropic,
ligand-gated ion channels. The three main classes of glu-
tamate ionotropic receptors have been named according to
their agonists: N-methyl-D-aspartate (NMDA), α-amino-
3-hydroxy-5- methylisoxazole-4-propionate (AMPA), or
kainate.
The onset of puberty results from the reactivation of the
gonadotropin-releasing hormone (GnRH) pulse generator
as a result of functional changes occurring in neuronal and
astroglial networks connected to the GnRH neuron. Gluta-
mate neurotransmission is the predominant mode of trans-
synaptic excitation used by hypothalamic neurons (1), and
several studies in various species have shown a marked stim-
ulatory effect of EAAs on the reproductive axis, particu-
larly at the time of puberty. Although the data discussed in
this review have been obtained in different species, the vast
majority of data come from the rodent and few from the
primate, including humans. Also, the mechanisms and their
developmental sequence may vary across species. There-
fore, the clinical implications are rather limited and animal
data cannot be extrapolated to human conditions.
Transsynaptic Regulation of GnRH
Secretion by Glutamate at Puberty
GnRH neurons receive direct glutamatergic innervation
(2,3), and it has been shown that glutamate stimulates GnRH
release from the adult hypothalamus in several species via
activation of NMDA and kainate receptors (4). Hypotha-
lamic glutamate content increases during prepubertal and
peripubertal development and reaches its maximum after
the onset of puberty (5). In addition, the release of glutamate
from preoptic area/medial basal hypothalamus explants or
from the preoptic area of the female rat in vivo increases
during the peripubertal period (6–8). Glutamate, NMDA,
and kainate stimulate GnRH secretion in immature rats (9–
11), monkey (12,13), and sheep (14). Moreover, NMDA re-
ceptor stimulation results in precocious puberty in rats (11,
15) and monkeys (16) and administration of the NMDA
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Sensitivity of the GnRH System
to Glutamate in Relation to Puberty
Developmental changes in NMDA receptors were ob-
served in several extrahypothalamic regions such as cortex,
hippocampus, and cerebellum (19–21). In the preoptic area,
the ratio of NR1 and NR2a and 2b receptor subunits was
reported to change as well (22) and could explain develop-
mental variations in sensitivity to NMDA receptor activa-
tion. The most dramatic increase in expression of NR1, a
subunit that is necessary for a functional NMDA receptor,
seemed to take place between fetal d 18 and postnatal d 10.
In the rat gray matter, genes encoding for the kainate recep-
tor subunits were expressed from fetal d 14 (23). Their ex-
pression went through a peak in the late fetal/early postnatal
period, when the contribution of non-NMDA receptors spe-
cifically involved in GnRH secretion was found to be pre-
dominant in our in vitro model (24). The mRNA editing of
different subunits of the non-NMDA receptors, which deter-
mines their gating characteristics, is developmentally regu-
lated (25) and may also contribute to the ontogenetic changes
in glutamate sensitivity.
Because glutamate receptors are ubiquitous in the central
nervous system (CNS) including the hypothalamus where
they play important roles in many processes throughout
development, the above observations raise the issue whether
the changes in glutamate receptor activity that affect GnRH
secretion are part of a global maturational process in the
CNS or result from a regionally specific mechanism. The
facilitatory control exerted by glutamate on GnRH neurons
increases gradually during the infantile–juvenile periods
as evidenced by the increased ability of glutamate receptor
stimulation to induce GnRH release during this time (26,
27). Gore et al. showed that NMA treatment started on d 25
resulted in accelerated elevation of GnRH mRNA levels and
sexual precocity. In addition, the percentage of GnRH neu-
rons double-labeled for NMDA-R1 subunit was found to
increase from 2–3% before or during puberty to 19% in
adulthood, whereas hypothalamic NMDA-R1 mRNA lev-
els increased before puberty between d 10 and 20 (28). This
indicates the possible discrepancies between global changes
and those specific of the GnRH neurons. In our in vitro con-
ditions where the developmental acceleration of pulsatile
GnRH secretion occurs between 10 and 25 d of age, the
NMDA receptor sensitivity was assessed by the sensitivity
to the use-dependent antagonist MK-801. Such a sensitivity
was found to increase dramatically in a gonad-independent
manner between d 10 and 25 (29,30) when a peak sensitiv-
ity is observed in consistency with the data obtained in vivo
by Cicero et al. (10).
Glutamate Production During Puberty
Glutamate concentrations in the rat hypothalamus increase
during prepubertal development (5). A major pathway for
glutamate biosynthesis is from glutamine under the action
of glutaminase (31). The mechanism of glutamate recycl-
ing in the brain involves reuptake by astroglial cells of the
glutamate released at the synapse level and transformation
into glutamine, which is delivered to glutamatergic neurons
where glutaminase causes transformation into glutamate.
Using hypothalamic explants of 15-d-old rats, we found that
glutamine was able to elicit GnRH release in a dose-depen-
dent manner similar to glutamate (32). In the presence of 6-
diazo-5-oxo-norleucine (DON), an inhibitor of glutaminase,
the glutamine-evoked GnRH secretion was prevented while
the glutamate-evoked secretion was not altered. DON also
significantly inhibited spontaneous GnRH secretion as well
as the veratridine-induced GnRH secretion. This indicates
that glutamate biosynthesis from glutamine is a prerequi-
site to the physiological mechanism of pulsatile GnRH secre-
tion. The DON concentrations required to inhibit the veratri-
dine-evoked GnRH secretion was lower at 15 d of age than
50, suggesting that glutaminase shows increased activity
around the onset of puberty when the frequency of pulsatile
GnRH secretion is increased as well. In a more recent study,
the glutamine-evoked secretion of GnRH compared with
that evoked by glutamate was used to provide an indirect
assessment of glutamate biosynthesis from glutamine. In
such conditions, a critical increase in glutamate biosynthesis
could be observed during the early postnatal period between
birth and 15 d (24), indicating that the increase in glutami-
nase activity was an early developmental event preceding
puberty. Roth et al., however, did not find any ontogenetic
change in glutaminase mRNA in the mediobasal hypothal-
amus and the preoptic area (33). Still, a limit in the signifi-
cance of such studies is the regional specificity of changes
in face of the ubiquity of the enzyme. If an increase in glu-
tamate biosynthesis from glutamine partly accounts for
the developmental increase in pulsatile GnRH secretion at
puberty, such a mechanism could be rather specific of the
neuronal–glial apparatus controlling GnRH secretion.
GnRH Inhibitory Autofeedback
Through Glutamate Receptors
We have described an autofeedback of GnRH on pulsa-
tile GnRH secretion in the rat hypothalamus. This inhibitory
autofeedback is mediated by the GnRH1–5 subproduct fol-
lowing degradation of the decapeptide by the prolyl endo-
peptidase (PEP) and involves the NMDA receptors but not
the kainate receptor subtype (34). This mechanism operates
already in the fetal hypothalamus, but with minimal impact
due to the prominent role of kainate receptors at that age
(24). Postnatally, the restricting effect of PEP on pulsatile
GnRH secretion appears to be maximal during prepuberty,
whereas it is reduced at 25 d and subsequently (35). In the
monkey, however, no evidence of such an inhibitory auto-
feedback could be obtained because intracerebroventric-
ular administration of GnRH or a GnRH antagonist did not
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alter the electrophysiological correlates of the GnRH pulse
generator (36).
Coordination of Glutamate and GABA
Regulation of GnRH Secretion at Puberty
Glutamatergic and GABAergic neurotransmissions are
critical opposing components of the onset of puberty. Sev-
eral observations suggest that they are strongly interdepen-
dent. Because glutamate is the natural precursor of GABA,
any change in glutamate availability could affect GABA
synthesis. Moreover, besides their direct action on GnRH
neurons, glutamatergic neurons control GABAergic neu-
rons. They inhibit GABA transmission through AMPA and
kainate receptors (37–39). The kainate receptor–mediated
stimulation appears to be exerted directly on GnRH neurons,
while the NMDA-mediated stimulation may require inter-
neurons (28). It is conceivable that the decrease in GABA
transmission preceding puberty results from an increase of
kainate receptor–mediated inputs to hypothalamic GABA-
ergic neurons. An additional glutamate–GABA interaction
can lie on NMDA receptors with differential effects related
to molecular subunits of the receptors because we showed,
through the use of antisense oligonucleotides, that the NR2A
subunit mediated a facilitatory effect on GnRH secretion in
vitro, whereas the NR2C subunit was involved in a GABA-
ergic inhibitory pathway (40). In this paradigm of rat hypo-
thalamic explant, we also found that onset of puberty was
preceded by a concomitant increase in NMDA receptor–
mediated stimulation and GABA receptor–mediated inhi-
bition of pulsatile GnRH secretion in vitro (41).
Neuron-to-Glia Signaling
Mediated by EAA During Puberty
Traditionally, astrocytes have been considered as having
a limited structural role in the brain, but evidence has been
obtained during the past few years that they play an active
role in synaptic communication by exchanging information
with the synaptic elements. The increase in GnRH secretion
at puberty requires an increase in transsynaptic glutamater-
gic inputs as well as the activation of a glia-to-neuron signal-
ing pathway mediated by erbB receptors and their ligands
operating in the hypothalamic astrocytes. Transforming
growth factor alpha (TGF-α) and neuregulin (NRG) stimu-
late GnRH secretion indirectly via the following sequence
of events: activation of the erbB-1 and erbB-4 receptors,
respectively, release of bioactive substances such as prosta-
glandin E2 (PG E2) and stimulation of GnRH by these sub-
stances (42–44). Astrocytes are endowed with glutamate
receptors (45,46) and respond to glutamate stimulation. It
has been shown that hypothalamic astrocytes express the
metabotropic glutamate receptor mGluR5 and the AMPA
receptors GluR2 and GluR3 subunits. The mechanisms relat-
ing the glutamatergic neurotransmission and the erbB-medi-
ated signaling have been described recently (47). The com-
bined activation of ionotropic and metabotropic glutamate
receptors located on astrocytes enhances the functional capa-
bility of the erbB system by recruitement of the erbB recep-
tors to the cell membrane, physical approximation of the
receptors to their membrane-bound ligands, phosphoryla-
tion of the erbB receptors, and increase of erbB receptor
gene expression. Glutamate receptor–induced erbB trans-
phosphorylation requires a processing of the membrane-
bound erbB ligands by metalloproteases. This mechanism
may be used to coordinate the activation of glutamatergic
neurons and astroglial cells during puberty, in addition to the
coordination of neuron-to-neuron communication requir-
ing NMDA and kainate receptors.
Nell-2
Nell-2, a neuron-specific gene, has recently been reported
to be selectively expressed in glutamate neurons through-
out the brain. Nell-2 is a positive regulator of glutamatergic
transmission and appears to be a required component of the
glutamate-dependent activational process leading to the ini-
tiation of puberty because its blockade using antisense oligo-
nucleotides results in delayed puberty (48).
Sex Steroid Interaction with Glutamate
Receptor–Mediated Release of GnRH
Among the systems regulating the hypothalamic–pitu-
itary–gonadal axis, the estradiol-mediated feedback on the
hypothalamus has been extensively studied and its impor-
tance during the reproductive cycle of the adult female has
been clearly demonstrated (49). Estradiol can act through
two nuclear receptors (called ERα and ERβ) that, upon acti-
vation, will act as transcriptional enhancers or repressors
by binding to specific DNA sequences called ERE or estro-
gen responsive element (50). These effects are known as
long-term or genomic effects and are responsible for the
positive and negative feedback effects of estradiol on the
hypothalamus (49,51). In addition to these genomic effects,
estradiol was also shown to act rapidly and directly on cells
or through the activation of second messengers such as pro-
tein kinases (52).
The common concept that estradiol should act on GnRH
neurons through intermediate cells (49) was challenged
after the expression of functional ERβ in GnRH neurons has
been reported and confirmed (53–55). The possible role
of estrogen in the onset of puberty has not been widely ex-
plored. There is an increased risk of precocious puberty in
girls exposed to environmental estrogens (56). In the rat,
Ramirez et al. have reported that an injection of estradiol
in the immature female induces precocious puberty (57).
This advancement of the pubertal onset could be due to an
increased stimulation of the GnRH secretion as it has been
reported that estradiol increased the responsiveness of the
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immature hypothalamus to stimulatory peptides (58). The
effects of estradiol on the onset of puberty could also be
mediated by the activation of the neuregulin receptors that
have been involved in the onset of puberty and can be reg-
ulated by estradiol (43). In addition, we also reported that
estradiol increased the GnRH pulse frequency after admin-
istration in vitro and in vivo (59). Our in vitro studies indi-
cate that estradiol increased the pulsatile GnRH secretion
through a mechanism involving the ERα subtype and the
kainate receptor. Although the implication of the glutama-
tergic system in triggering the onset of puberty is well known,
only the NMDA receptor subtype has been involved in this
process in vivo in the monkey (60) and in vitro in the rat
(61). The participation of the kainate receptor in the estra-
diol-induced advancement of puberty is interesting and leads
to the hypothesis that, during development, as the gonads
increase their hormonal secretion, the kainate receptors get
activated and are responsible for the estradiol-mediated acti-
vation of the GnRH system. As the immature female goes
into adulthood, these specific interactions between the estro-
gen and the kainate receptor might be integrated in the reg-
ulatory mechanisms of the estrous cycle. This hypothesis is
supported by previous studies showing that, in the afternoon
of proestrus, nearly half of activated GnRH neurons express
kainate receptor subunits (62). In addition, the AMPA/kain-
ate receptor antagonist DNQX can block the estradiol-in-
duced LH surge in ovariectomized rats (63).
Precocious Puberty Associated with
Hyperglycinemia: Illustration of NMDA
Involvement in Puberty in Humans
Until recently, there was no evidence of NMDA recep-
tor involvement in the regulation of puberty in human. Bour-
guignon et al. reported a case of precocious puberty in a
11-mo-old girl suffering from nonketotic hyperglycinemia
(NKH) (64), which is a severe genetic disease caused by
an inherited defect in the enzymatic system cleaving gly-
cine. This results in an increase of glycine concentration in
the cerebrospinal fluid. Some nonketotic hyperglycinemia
symptoms involve the inhibitory strychnine-sensitive gly-
cine receptors (65), whereas the pathogenesis of seizures
involves the excitatory strychnine-insensitive glycine recep-
tors belonging to the NMDA–receptor complex (66). The
occurrence of precocious puberty in this patient was thought
to result from excessive stimulation by glycine of the NMDA
receptors linked to the GnRH neurons. This hypothesis was
supported by in vitro observations. Glycine increased the
pulse frequency of GnRH secretion from hypothalamic
explants of immature female rats and this effect was pre-
vented by 7-chlorokynurenic acid, a glycin antagonist at the
NMDA receptor complex. Regression of pubertal devel-
opment under anticonvulsive treatment with GABA ago-
nists suggested that the stimulatory effect of glycine could
be overcome by GABA receptor–mediated inhibition. Those
GABA agonists suppressed the stimulatory effect of glycine
in vitro as well as the developmental increase in the fre-
quency of pulsatile GnRH secretion.
Conclusion
Glutamate is an excitatory amino acid that can play
several roles in the hypothalamic mechanism of puberty.
The evidence, convincing in rodents, is however scarce in
humans. Glutamate is likely to be more generally a critical
neuromediator in the different neuroendocrine functions as
suggested by the panhypopituitarism associated with dis-
ordered control of energy balance following neonatal insult
of glutamate-sensitive cells by monosodium glutamate (67).
Although such a paradigm could be related to some clinical
conditions with early and generalized failure of hypothal-
amic homeostatic mechanisms, there are still few clinical
data supporting the role of glutamate in human neuroendo-
crine physiology and pathophysiology.
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